OmniComm Systems, Inc. Drives Industry Discussion On Designing Adaptive Clinical Trials

Company To Host Xtalks Webinar Featuring Dr. Mark Chang Of Millenium Pharmaceuticals

FT. LAUDERDALE, FL - September 5, 2007 - /MarketWire/ - OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced Dr. Mark Chang, co-author of the book "Adaptive Design Methods in Clinical Trials" and the upcoming book "Adaptive Design Theory and Implementation Using SAS and R" will be the feature guest speaker in this thought provoking discussion on designing Adaptive Clinical Trials.

Key strategies and technologies for facilitating Adaptive Clinical Trials are evolving for drug development. Join this interactive Webinar and hear from key industry experts on this timely topic.

Who:	Dr. Mark Chang, Director of Biostatistics, Millennium Pharmaceuticals Mr. Ken Light, Senior Vice President, Professional Services, OmniComm Systems, Inc.
What:	Designing Adaptive Clinical Trials - Part 2 "Improve Trial Design Efficiency" An adaptive design is a design that allows for modifications to the on-going trial based on either the observed data from the trial or external information. It is recognized that adaptive designs can improve the efficiency of a trial design and increase the probability of success. During this webinar participants will study different adaptive designs through trial examples including: (1) sample-size re-estimation, (2) drop-loser design, (3) response-adaptive randomization, (4) Biomarker-adaptive design and (5) adaptive dose-escalation design. "EDC Tools and Integrated Technologies to Support Adaptive Trials" The widespread growth of Electronic Data Capture (EDC) technology is viewed as a fundamental enabler to allow agile trial execution and provide support for early data access, mid-study trial changes, security, traceability and proactive data analysis. During this Webinar, we will review how the correct implementation of EDC technology, along with integration to other technology enablers, is paramount to achieving and sustaining the adaptive trial paradigm shift that aims to increase the overall effectiveness of clinical trials.
When:	September 14, 2007 from 1:00pm - 3:00pm EDT
Where:	To register for this event please visit www.xtalks.com/designingact.ashx

About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.

OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. The company has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Germany, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer
Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

Back